Purpose: The purpose of this study is to investigate the utility of contrast-enhanced magnetic resonance imaging (CE-MRI), diffusion-weighted MRI (DW-MRI), and 68 Ga-DOTATOC positron emission tomography/computer tomography ( 68 Ga-DOTATOC PET/CT) in the assessment of response to loco-regional peptide receptor radiotherapy (PRRT) with 90 Y-/ 177 Lu-DOTATOC in patients with hepatic metastases from gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). Procedures: CE-MRI, DW-MRI, and 68 Ga-DOTATOC-PET/CT images were acquired before and 3 months after one to two cycles of intra-arterial 90 Y-/ 177 Lu-DOTATOC therapy in 14 patients (nine female, five male; mean age, 54±9 years; range, 41-69 years) with hepatic metastases from GEP-NET. A total of 38 liver metastases were defined as target lesions for which the longest diameter, mean apparent diffusion coefficient (ADC mean ) and maximum standardized uptake value (SUV max ) were assessed. Based on changes in size on follow-up imaging, target lesions were classified as responding (RL) or nonresponding (NRL). Relative changes in tumor size, ADC mean , and SUV max were compared between the two subgroups. Results: A total of 27 responding and 11 nonresponding lesions were successfully evaluated. Mean ADC mean increased significantly in RL (p=0.011) as well as NRL (p=0.025). A significant correlation was found between baseline ADC mean and both the percent ADC mean change (p= 0.033) and decrease in lesion size after therapy (diameter p=0.006; volume p=0.002). SUV max of RL declined significantly by 24.1 % (p=0.014) and remained nearly unchanged in NRL. The change of SUV max correlated significantly with the pretreatment SUV max (pG0.001) and the change in lesion diameter (p=0.009). NRL with an ADC mean change 90.31×10 −3 mm 2 /s on first follow-up imaging showed a decrease in size in the long-term course. Conclusion: These results suggest that both DW-MRI and DOTATOC-PET imaging provide potential biomarkers for early assessment of treatment and stratification of therapy response, Sarah Wulfert and Clemens Kratochwil contributed equally to this paper.
Introduction
A lthough rare, neuroendocrine tumors (NET) have steadily increased in frequency over the last 30 years, mainly due to raised awareness and improved diagnostics [1] [2] [3] [4] [5] [6] . Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) represent approximately 75 % of all NET [7] . This entity often presents with liver metastases, which is a strongly negative prognostic indicator [8, 9] . Thus, in the recent years many efforts have been made to optimize the therapy of inoperable focal GEP-NET liver metastases [10] [11] [12] . Besides the advancements in conventional therapeutic procedures such as percutaneous ablative therapies, surgical resection or trans-arterial chemotherapy, there has been notable progress in customized palliative therapies for metastatic GEP-NET utilizing targeted therapeutic radiopharmaceuticals [13] [14] [15] [16] .
A relatively new approach in this domain is to utilize peptide receptor radionuclide therapy (PRRT) by chelating 90 Y or 177 Lu to DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTA-TOC) and injecting it selectively into the hepatic artery [17, 18] . Most GEP-NET primaries and metastases demonstrate increased expression of somatostatin receptor [19, 20] . Thus, the radiolabeled somatostatin analog DOTATOC targets malignant tissue with relatively minor damage to surrounding healthy structures. However, the assessment of response to this treatment remains a challenging task, as it primarily induces tumor lysis and a loss of cellular integrity which may not immediately result in reduced tumor size [21] . Thus, additional methods are needed to determine early responses to this locoregional therapy. In this study, we analyzed diffusion-weighted magnetic resonance imaging (DW-MRI) and 68 Ga-DOTATOC positron emission tomography/computer tomography ( 68 Ga-DOTATOC PET/CT) images to determine if functional imaging could provide an early indicator of tumor response to PRRT.
Patients and Methods
Thirty-six patients with refractory hepatic metastases from GEP-NET were treated with intra-arterial 90 Y-/ 177 -Lu-DOTATOC. Institutional review board approval was obtained. All patients provided informed consent. Fourteen of these patients (nine female, five male; mean age, 54±9 years; range, 41-69 years) underwent DW-MRI before and after one to two cycles of intra-arterial PRRT and were thus included in this retrospective study. For 11 of these 14 patients, PET/CT images at the same time points were also available for review. Of the 14 patients, eight had a neuroendocrine tumor of the pancreas, four of the intestine, one of the stomach, and one patient had a neuroendocrine tumor of unknown primary. Eight of the 14 patients had already undergone one to three cycles of conventional intravenous PRRT without sufficient response. In order to minimize bias, no more than three hepatic lesions (92 cm longest diameter) per patient were analyzed. The measurement of mean apparent diffusion coefficient (ADC mean ) values had to be possible on at least three consecutive sections for each metastasis on the baseline DW-MRI. During the follow-up period, none of the patients received concomitant treatments except symptomatic therapy with somatostatin analogs.
Catheter Placement and Treatment Regimen
A 4-French catheter (Sidewinder S1) was placed in the celiac artery via transfemoral access using the Seldinger technique with local anesthesia. Subsequently, a microcatheter (Progreat) was inserted coaxially and advanced to the common hepatic artery or proper hepatic artery. In cases of anatomic variation, the largest arterial feeder was cannulated. The catheter was used to deliver 90 Y-and/or 177 Lu-DOTATOC. To minimize renal toxicity, 1,000 ml of a nephroprotective solution containing 30 g lysine and 30 g arginine was applied simultaneously.
MR Imaging Technique and Analysis
Magnetic resonance examinations were performed on a 1.5-T MR system (Avanto, Siemens Medical Systems, Erlangen, Germany). Unenhanced T1-weighted (gradient echo, TR=192 ms, TE= 4.76 ms, 256×154 matrix) and T2-weighted (HASTE, TR= 801 ms, TE=69 ms, 384×213 matrix) fast spin echo axial imaging was performed before DW-MRI and Gd-EOB-DTPA (Primovist®, Bayer Schering, Berlin, Germany) administration for contrastenhanced magnetic resonance imaging (CE-MRI). DW-MRI was performed with a breath-hold single-shot echo planar sequence (TR=12,200 ms; TE=67 ms; FOV 430 cm; section thickness5 mm; b values 50, 300, and 600 s/mm 2 ; voxel 3.3×3.3×5, EPI factor 112).
The acquisition of delayed postcontrast MR data started with the i.v. administration of 0.1 mmol/kg body weight of the contrast agent Gd-EOB-DTPA with an infusion rate of 1.5 ml/s followed by a 30-ml saline bolus. Imaging was performed with a T1w volumetric interpolated breath hold examination (VIBE) with 3.41 ms TR, 1.18 ms TE, 4 mm slice thickness, 320×180 matrix, and 72 axial slices with an acquisition time of 20 s for each dataset.
Two to three target lesions per patient were selected in the hepatocyte specific contrast phase 15 min p.i. (late enhanced) which was considered the gold standard for lesion delineation on the baseline examination and then were followed on the later MRI [5] .
Because of the favorable tumor to liver contrast, the longest diameter (LD) of each lesion was manually measured on lateenhanced MR images. For the assessment of tumor volume, the workstation Ziostation® (Ziosoft Inc., Redwood City, USA) was used. After manual delineation of the lesions' borders on several slices, an automatic interpolation and calculation of tumor volume in cubic centimeters was acquired by the software.
DW-MRI data was analyzed using in-house developed software (DKFZ, Heidelberg, Germany) based on Interactive Data Language (IDL, Exelis Visual Information Solutions, Boulder, CO, USA). For each target metastasis, regions of interest (ROI) were placed in three different layers, covering as much of the lesion as possible. For each layer, the ADC mean was calculated by the software using the formula S=S 0 exp(−b·ADC). Using the three b values (b=50, 300, and 600 s/mm 2 ), a nonlinear Levenberg-Marquardt fit was used to calculate S 0 and ADC mean . The mean value of the three measurements per lesion was taken as the representative value for further analysis. Additionally, ADC mean values of normal-appearing liver parenchyma and spleen were assessed in the same manner for every patient. ADC is a marker for the diffusion of water molecules based on Brownian motion. As it is inversely proportional to the cellularity of biological tissue, ADC values are high in necrotic areas with unrestricted diffusion and are low in vital tissues with high cell density and intact cell membranes such as viable tumor. After anticancer therapies, fibrotic remodeling can also lead to a decrease in ADC, whereas apoptosis and therapy-induced necrosis increase the ADC.
PET/CT Imaging Technique and Image Analysis
The PET studies were acquired with a Biograph 6 PET/CT (Siemens Medical Systems, Erlangen, Germany). Imaging was started 40±10 min after the i.v. injection of 84-196 MBq of 68 Ga-DOTATOC. Static emission scans-corrected for dead time, scatter, and decay-were acquired from the vertex to the proximal legs, requiring eight bed positions (4 min each). Contrast-enhanced CT (CE-CT) was performed as a part of the PET/CT. The iodinated contrast medium (Imeron 400, Bracco Diagnostics, Milan, Italy) was injected at a flow rate of 4 ml/s. The liver and abdomen were initially examined without contrast media (130 keV, 30 mAs, CareDose), followed by an arterial phase (25 s delay) and a portal venous phase (60 s delay). The low-dose CT without contrast agent was used for attenuation correction. Slice collimation was 6× 1.0 mm, pitch factor 1.5, 110 keV, 95 mAs (CareDose), matrix 512×512, rotation time 0.6 s, reconstructed to a slice thickness of 1.25-and 0.8-mm increment with a B30-kernel. Secondary raw data were reformatted to a slice thickness of 5 mm with a 2.5 mm increment in the coronal and axial view. The images were iteratively reconstructed with the ordered subset expectation maximization (OSEM) algorithm using four iterations with eight subsets and Gaussian filtering to achieve an in-plane spatial resolution of 5 mm at full-width half-maximum. Calculation of the maximum standardized uptake value (SUV max ) of a target lesion was performed after identification of the lesion on both PET/ CT and MRI. Circular ROIs were drawn around these areas of increased uptake in transaxial slices and automatically adapted by e.soft software (Siemens Medical Systems, Erlangen, Germany) to a three-dimensional volume, in which the SUV max was determined automatically by the software. Analogously, the SUV max of normalappearing liver parenchyma and spleen was evaluated after placing a ROI into a region without tumor infiltration (the region for normal liver parenchyma was selected after double checking with MRI, CT, and PET).
Assessment of Therapeutic Response
For each metastatic lesion, the following data was assessed: tumor volume (TV), LD, ADC mean , and SUV max before and after treatment. Response to therapy was determined on a lesion-bylesion basis by evaluating changes in metastasis size between baseline and follow-up MRI. A metastasis was classified as responding lesion (RL) if its LD decreased or did not change and nonresponding lesion (NRL) if the tumor diameter increased. 
Statistical Analysis
All statistical analysis was carried out with the free software environment "R". A p value of 0.05 was considered statistically significant. The quantified variables are described as median and interquartile range (IQR) or as percentages for discrete variables. For data comparison within the same groups, the Wilcoxon signedrank test for related samples was applied. Intergroup comparisons were performed with the Mann-Whitney test for independent samples. Correlations between the assessed parameters (LD, TV, SUV, and ADC mean ) and between their percent changes from baseline were determined using Spearman's rank correlation coefficient.
Results
Thirty-eight metastases were defined based on delayed enhanced MRI as target lesions. Thirty-seven of these target lesions could be identified and analyzed on baseline DW-MR images. Of the 11 patients with PET/CT data available, all 29 of their target lesions as identified on CE-MRI were present on the baseline PET/CT. Due to therapy response, two of 37 target lesions could not be identified on DW-MRI after PRRT. According to changes in lesion size, 27 metastases (71 %) were classified as RL and 11 metastases (29 %) as NRL. Before therapy, LD of RL was 30.4 mm (IQR, 13.4) and the LD of NRL 33.2 mm (IQR, 18.2). There was no significant difference between the median pretreatment size of the two groups (p=0.159). Baseline TV of RL was 9.6 cm 3 (IQR, 7.9) and for NRL was 18.1 cm 3 (IQR, 39.9; p=0.147). On follow-up MRI 3 months after the last treatment cycle, the LD of RL decreased significantly by 11.2 % (IQR, 21.5; pG0.001), whereas NRL showed a LD increased significantly by 8.5 % (IQR, 16.4; pG0.001).
The initial ADC mean of RL was 1.21×10 −3 mm 2 /s (IQR, 0.61) and of NRL 1.09×10 −3 mm 2 /s (IQR, 0.35; p=0.392). On follow-up DW-MRI, ADC mean increased significantly both in RL (+10.6 %; IQR, 38.8; p=0.011) and in NRL (+18.1 %; IQR, 27.3; p=0.025) with the percentage of change in ADC mean values of NRL being higher than those of RL (Figs. 1a and 2 ). Baseline ADC mean of all lesions correlated weakly but significantly negative both with LD (r=−0.441; p=0.006) and TV (r=−0.500; p=0.002).
Although most RL demonstrated an increase in ADC mean after PRRT, seven lesions were found to decrease in ADC mean value by a mean of −26.8 % (Fig. 2) .
Additionally, the ADC mean of normal liver parenchyma (n=14) and of the spleen (n=11) was assessed. Three patients had undergone prior splenectomy. Neither the ADC mean values of normal liver parenchyma nor of spleen tissue showed a significant change after therapy (p90.05).
On PET/CT images, 29 of the target metastases could be analyzed before and 27 after therapy. Baseline median SUV max of RL was 28.48 and decreased by 24.1 % on follow-up PET/CT (p=0.014), whereas SUV max of NRL (baseline, 22.03) increased by 3.9 % (p = 0.910; n.s.; Fig. 1b) . Baseline SUV max of the two subgroups did not show a significant difference. A negative correlation was observed between pretreatment SUV max and the percent change of SUV max after therapy (r=−0.769; pG0.001) as well as with the percent change of LD (r=−0.482; p=0.009) and TV (r=−0.516; p=0.005). Fig. 2 . ADC mean of nonresponding lesions before and after PRRT (left) and responding lesions before and after PRRT (right). In both presented subgroups, the median ADC mean value was found to be lower prior to PRRT compared to the ADC mean value after intervention. Seven target lesions in the responding subgroup declined in ADC mean after therapy (mean change, −26.8 %). The SUV max of spleen tissue increased significantly by a median of 24.3 % (p=0.039) during the observation period, whereas the SUV max of normal liver parenchyma showed no significant changes. The change of SUV max in the spleens did not correlate significantly with change of SUV max in the target lesions. Table 1 provides a short overview over the results listed above. Figures 3 and 4 show an example of a responding lesion and of a nonresponding lesion, respectively, before and after PRRT.
As our results showed a stronger increase of ADC mean in NRL than in RL after the first follow-up, we analyzed the 11 NRL again later in the course of treatment. All of the 11 NRL could be analyzed on a second follow-up imaging with CE-MRI in mean 6 months after first follow-up. The examined patients had undergone further intra-arterial DOTATOC therapy in the interval. Three of the NRL finally decreased in size, while eight had grown compared to the baseline LD.
In the three lesions that demonstrated a decrease in size and volume, a mean ADC mean increase of 29.0 % from baseline to first follow-up and a mean decrease in SUV max of 19.0 % was observed (Fig. 5) . The eight growing lesions demonstrated an increase in ADC mean of 12.0 % from baseline to first follow-up. In five of these eight lesions, PET/CT data was available (baseline and follow-up). Here, a mean increase of SUV max of 22.4 % was measured. Due to the small number of cases, we refrained from a statistical analysis of this finding.
Discussion
In this retrospective study, the ADC mean of neuroendocrine liver metastases increased significantly both in RL and in NRL. Before therapy, there was no significant difference in the ADC mean of the two groups. Baseline-ADC mean of the assessed target lesions correlated inversely with the percent change of LD (r=−0.44; p=0.006) and volume (r=−0.50; p=0.002) under PRRT. This shows that the higher the ADC mean before therapy, the more the metastases decreased in size. In other studies, patients with a higher baseline ADC showed a worse response to therapy. Koh et al. [22] investigated hepatic metastases of colorectal cancer under chemotherapy and noted a significantly higher ADC in nonresponding lesions before therapy than in responding lesions (p=0.002). They also found an inverse correlation of baseline ADC and percent reduction in lesion size (r=−0.58; p=0.03). Cui et al. [23] also showed an inverse correlation of these values for the same tumor entity but under concomitant chemoradiotherapy (r=−0.293; p=0.006). It is assumed that tumors with higher baseline ADC have some necrotic areas, which could indicate hypoxia mediated radioresistance. However, this hypothesis cannot be generalized for all tumor entities. In a study by DeVries et al. [24] , no differences between baseline ADC value was found for responders and nonresponders in rectal carcinoma, as is also the case in our study.
Seven responding lesions had decreased ADC mean values after PRRT. Further assessment of these target lesions demonstrated that they had a high mean pretherapy ADC mean of 1.81×10 −3 mm 2 /s with four of the lesions having a baseline ADC mean of 92.0×10 −3 mm 2 /s. It is possible that the ADC mean change is related to fibrosis as these lesions also exhibited marked reductions in size.
In general, a low ADC is associated with high cell density [25, 26] and low water diffusivity (Fig. 6 ). This could negatively affect the saturation of somatostatin-receptors (SSTR) with 90 Y-/ 177 Lu-DOTATOC because the ability of the radiopeptide to diffuse in densely packed cells could be hindered. As the uptake of radiolabeled DOTATOC is essential for inducing radiation damage in tumor tissue [17, 27, 28] , this could explain why there was a minor response in lesions with high cell density. This thesis is supported by the significant correlation of ADC mean and SUV max before therapy (r=0.50; p=0.007). At higher baseline ADC mean -and thus lower cell density-we found a higher uptake of 68 Ga-DOTATOC in PET/CT. In future studies, the additional evaluation of minimum ADC (ADC min ) could be of interest, as this value has shown a correlation to SUV max in a very recent study [29] . Further investigation will be needed to determine the impact of ADC min assessment.
In our study, the ADC mean of RL and NRL increased significantly under PRRT. This increase can either be ascribed to therapy-induced cell damage or to new intrametastatic necrotic areas which spontaneously arise in proliferating tumors. The differentiation between these two options is challenging [30, 31] . In RL, the increase in ADC mean was accompanied by a decrease in SUV max , which implies a cell loss due to PRRT. In NRL, the rise of ADC mean came along with tumor growth and an increase in SUV max . Conceivably, there can be a combination of newly formed necrotic areas that increase the ADC mean and proliferating vital tumor tissue which causes the lesions' growth and the higher uptake of 68 Ga-DOTATOC. The ADC mean of normal liver tissue and spleen showed no significant differences after therapy. This speaks for the specific impact of the PRRT on tumor tissue while sparing healthy surrounding structures.
Before therapy, the SUV max of RL was higher than the SUV max of NRL; however, the difference was not significant. Gabriel et al. [32] also found no significant difference in baseline SUV max of responders and nonresponders in their study evaluating the efficacy of intravenous PRRT with 68 Ga-DOTATOC-PET. Campana et al. [33] investigated the role of 68 Ga-DOTANOC uptake as a prognostic factor in neuroendocrine tumors. Patients with partial remission or stable disease showed a significantly higher SUV max than patients with progressive disease.
In our study, the baseline SUV max of the target lesions correlated inversely with the percent change of LD, volume, and SUV max under PRRT. A higher pretreatment SUV max was associated with a greater decrease of lesion size and SUV max during therapy. These results are endorsed by the report of Koukouraki et al. [34] , in which an elevated baseline SUV max Fig. 5 . Neuroendocrine liver metastasis in a 44-year-old male. After one cycle of PRRT (first follow-up), the LD and the volume of the target lesion increased and it was thus categorized as nonresponding lesion. ADC mean increased from 1.82×10 −3 to 2.36×10 −3 mm 2 /s. Remarkably, there was a decrease in maximal SUV of 68 Ga-DOTATOC in this first follow-up imaging from 29.5 to 23.0. To confirm if this decrease was followed by a later decline in LD and volume of the metastasis after further PRRT, a second follow-up examination was analyzed 11 months after baseline imaging. Here, the size of the target lesion had decreased below its baseline values.
was associated with higher binding of 68 Ga-DOTATOC on SSTR2 and thus with a favorable effect of PRRT.
SUV max of RL decreased by 24.1 % whereas it increased by 3.9 % in NRL. A significant correlation was found between percent change of LD/volume and percent change of SUV max under PRRT. Therefore, a decrease in lesion size often was accompanied by a decrease of SUV max and vice versa. Kroiss et al. [35] also found a lower SUV max in hepatic metastases under PRRT, and Gabriel et al. [32] reported a higher relative decrease of 68 Ga uptake under systemic PRRT in responders than in nonresponders.
However, Gabriel et al. [32] could not find clear correlations of SUV values with outcome parameters. In this study, the decrease in SUV max under PRRT with concomitant shrinking of the target lesions can probably be ascribed to necrosis and apoptosis of tumor cells. The second follow-up of the nonresponding lesions showed that lesions with a decrease in SUV max after the first follow-up also eventually decreased in size after longer time periods. The percentage decrease of SUV max under PRRT could thus suggest therapy response.
In this study, the SUV max of the spleen (n=8) rose by 34.0 % in the observation period, whereas the 68 Ga-DOTATOC uptake in the liver remained stable. Haug et al. [36] reported already that PRRT can influence the 68 Ga-DOTATATE uptake in neuroendocrine tumors and the spleen with the SUV max in the spleen being lower before therapy. The leading thought here is that a successful PRRT reduces the tracer uptake specifically in the tumor and hence more tracer is left in the blood stream for physiological uptake in the spleen and other organs. This is supported by the observation of an unchanged ADC mean in the spleen.
Conclusion
High initial SUV max values in 68 Ga-DOTATOC-PET as well as high ADC mean values in DW-MRI both suggest better therapeutic response to PRRT. A decrease in SUV max in DOTATOC-PET is a good surrogate for early response assessment after one to two cycles of therapy. In contrast, DW-MRI presents both treatment-induced tumor necrosis and a higher tumor cellularity due to continuing tumor growth resulting in the same changes of ADC mean values. Therefore, in the setting of NET, the ADC mean value-while a promising biomarker-should be interpreted only in combination with SSTR expression or imaging morphology. 
